Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hemoglobin Sc Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    119 result(s) found for: Hemoglobin Sc Disease. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2010-021377-36 Sponsor Protocol Number: BO22334 Start Date*: 2010-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: “Estudio de fase III en dos etapas, abierto, internacional, multicéntrico, aleatorizado y controlado para investigar la farmacocinética, la eficacia y la seguridad de rituximab s.c. conjuntamente c...
    Medical condition: Linfoma Folicular (LF) CD-20 psoitivo grado 1-2, 3a sin tratar previamente Previously untreated, CD20-positive follicular lymphoma (FL) grade 1-2, 3a
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061170 Follicle centre lymphoma, follicular grade I, II, III LLT
    12.1 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DK (Completed) DE (Completed) FR (Completed) FI (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002370-39 Sponsor Protocol Number: ALXN1210-PNH-303 Start Date*: 2019-07-02
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxys...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) SE (Completed) FI (Completed) CZ (Completed) ES (Ongoing) AT (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-004928-38 Sponsor Protocol Number: GEICAM/2012-07 Start Date*: 2013-02-19
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A phase III clinical trial to evaluate patient´s preference of subcutaneous trastuzumab (SC) versus intravenous (IV) administration in patients with HER2 positive Advanced Breast Cancer (ABC) who ...
    Medical condition: Patients with HER2 positive Advanced Breast Cancer receiving trastuzumab with or without CT or HT therapy for at least four months without evidence of disease progression and a life expectancy of a...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-000525-25 Sponsor Protocol Number: 61186372NSC3004 Start Date*: 2022-09-05
    Sponsor Name:JANSSEN CILAG INTERNATIONAL NV
    Full Title: A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous on Body Deliv...
    Medical condition: EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001087-30 Sponsor Protocol Number: CT-P13_3.8 Start Date*: 2019-07-25
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderat...
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) SK (Completed) FR (Completed) PL (Completed) DE (Completed) GR (Completed) HU (Completed) ES (Completed) AT (Completed) BG (Completed) HR (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004185-34 Sponsor Protocol Number: 54767414MMY2065 Start Date*: 2019-05-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Mu...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) DK (Completed) NL (Prematurely Ended) FR (Ongoing) ES (Ongoing) PL (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003414-10 Sponsor Protocol Number: NN9536-4374 Start Date*: 2018-05-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes
    Medical condition: 1. Obesity 2. Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002150-31 Sponsor Protocol Number: 20090302 Start Date*: 2012-08-29
    Sponsor Name:Amgen Inc
    Full Title: An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin alfa in Paediatric Subjects From Birth to Less than 1 Year of Age With A...
    Medical condition: Anaemia due to chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.1 10005329 - Blood and lymphatic system disorders 10002272 Anemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004032-75 Sponsor Protocol Number: ML20572 Start Date*: 2007-02-09
    Sponsor Name:Roche Pharma AG
    Full Title: An open-label, multi-center study to demonstrate the efficacy and safety of C.E.R.A when administered intravenously with pre-filled syringes (PFS) for the treatment of anemia in patients with chron...
    Medical condition: renal anemia due to chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058116 Nephrogenic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004220-30 Sponsor Protocol Number: BA058-05-019 Start Date*: 2018-07-25
    Sponsor Name:Radius Health, Inc.
    Full Title: A Randomized, Double blind, Placebo controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide SC for the Treatment of Men with Osteoporosis.
    Medical condition: Osteoporosis in men
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002323-38 Sponsor Protocol Number: GBG105GeparPiPPa Start Date*: 2022-08-29
    Sponsor Name:German Breast Group
    Full Title: A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-pos...
    Medical condition: Patients with early breast cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002871-40 Sponsor Protocol Number: HX575-308 Start Date*: 2012-02-28
    Sponsor Name:Hexal AG
    Full Title: Open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialy...
    Medical condition: anemia associated with chronic kidney disease in pre-dialysis and dialysis patients
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004851 10058124 Nephrogenic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003300-31 Sponsor Protocol Number: 20159460(c) Start Date*: 2017-06-13
    Sponsor Name:Hellenic Society for the Study of Bone Metabolism
    Full Title: Evaluation of the efficacy of Denosumab in adult patients with Langerhans Cell Histiocytosis (LCH) : a multiple-site, single arm, open label Clinical Trial.
    Medical condition: Langerhans Cell Histiocytosis (LCH) is a rare disease of unknown etiology with variable clinical course exhibiting both neoplastic and inflammatory features. It is characterized by the accumulatio...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010582-23 Sponsor Protocol Number: CNTO148ART3002 Start Date*: 2010-01-04
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) SE (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004552-21 Sponsor Protocol Number: BH20051 Start Date*: 2007-02-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in pati...
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058124 Nephrogenic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000952-28 Sponsor Protocol Number: 26866138-MMY-3021 Start Date*: 2008-12-17
    Sponsor Name:Janssen-Cilag International NV (JCI)
    Full Title: An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma
    Medical condition: The subject population comprises adult male and female subjects with multiple myeloma that has relapsed or progressed after prior systemic antineoplastic therapy, presence of measurable secretory d...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002815-28 Sponsor Protocol Number: AFX01-07 Start Date*: 2007-01-31
    Sponsor Name:Affymax, Inc.
    Full Title: A Phase 2, Open-label, Multi-Center, Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of AF37702 Injection (HematideTM) for the Maintenance Treatment of Anemia in Hemodialys...
    Medical condition: Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin
    Disease: Version SOC Term Classification Code Term Level
    8.1 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003572-23 Sponsor Protocol Number: GCP#01.01.030 Start Date*: 2017-12-27
    Sponsor Name:Gamida Cell Ltd
    Full Title: Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies
    Medical condition: Hemoglobinopathies
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10054658 Thalassemia LLT
    18.0 100000004850 10040645 Sickle cell disease NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000206-38 Sponsor Protocol Number: 54767414MMY3012 Start Date*: 2017-10-04
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Completed) ES (Ongoing) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA